SCHEMBL26075130

SCHEMBL26075130

CCOc1ccc(-c2ccc(-c3cc(C)c4cc(F)ccc4n3)cc2F)cc1

nearest known ligand 0.43

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ HMOX1 P09601 3/20 0.43
▸ KDM4E B2RXH2 4/20 0.42
▸ ALDH1A1 P00352 2/20 0.42
▸ PDE10A Q9Y233 2/20 0.42
▸ SMN1; SMN2 Q16637 2/20 0.42
▸ RAB9A P51151 2/20 0.42
▸ NPC1 O15118 2/20 0.42
▸ LMNA P02545 1/20 0.42
▸ HPGD P15428 1/20 0.42
▸ GAA P10253 1/20 0.41
▸ DHODH Q02127 6/20 0.41
▸ PLA2G2A P14555 1/20 0.41
▸ MEN1 O00255 2/20 0.41
▸ KMT2A Q03164 2/20 0.41
▸ HSD17B10 Q99714 1/20 0.41
▸ SCN9A Q15858 1/20 0.39
▸ MAPT P10636 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26075298 0.93 HMOX1 (0.45) HMOX1KDM4EALDH1A1PDE10ASMN1; SMN2
SCHEMBL26075148 0.92 PDE10A (0.43) KDM4EALDH1A1PDE10ASMN1; SMN2RAB9A
SCHEMBL26075339 0.92 DHODH (0.39) HMOX1PDE10ADHODHPLA2G2A
SCHEMBL26075237 0.91 PLA2G2A (0.44) KDM4EALDH1A1PDE10ASMN1; SMN2RAB9A
SCHEMBL26075234 0.91 DHODH (0.44) PDE10ADHODHPLA2G2A
SCHEMBL26075134 0.89 PTGS2 (0.47) HMOX1PDE10ASMN1; SMN2HPGDDHODH
SCHEMBL26075277 0.89 PLA2G2A (0.42) KDM4EALDH1A1PDE10ASMN1; SMN2RAB9A
SCHEMBL26075210 0.89 AURKA (0.47) HMOX1KDM4EALDH1A1SMN1; SMN2RAB9A
SCHEMBL26075885 0.89 HMOX1 (0.41) HMOX1KDM4EALDH1A1SMN1; SMN2RAB9A
SCHEMBL26075168 0.89 PDE10A (0.46) KDM4EALDH1A1PDE10ASMN1; SMN2RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230303710-A1 METHODS AND COMPOSITIONS FOR INHIBITION OF DIHYDROOROTATE DEHYDROGENASE IN COMBINATION WITH AN ANTI-CD38 THERAPEUTIC AGENT OHIO STATE INNOVATION FOUNDATION (US) 2023-09-28 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230303710-A1 METHODS AND COMPOSITIONS FOR INHIBITION OF DIHYDROOROTATE DEHYDROGENASE IN COMBINATION WITH AN ANTI-CD38 THERAPEUTIC AGENT DHODH, CD38, DPYD HMOX1 329/4885KDM4E 1396/4885ALDH1A1 88/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback